MET and breast carcinoma: To target the c-Met/β1 complex in breast cancer cells, we treated cells with OS2966, a therapeutic humanized β1 integrin–neutralizing antibody that we showed to inhibit the c-Met/β1 complex formation in MDA-MB-231 cells (Figure 5A).